These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 33207106)

  • 1. Azacitidine and Venetoclax in AML. Reply.
    DiNardo CD; Wang J; Pratz KW
    N Engl J Med; 2020 Nov; 383(21):2088-2089. PubMed ID: 33207106
    [No Abstract]   [Full Text] [Related]  

  • 2. Azacitidine and Venetoclax in AML.
    Moore JW; Pelcovits A; Reagan JL
    N Engl J Med; 2020 Nov; 383(21):2088. PubMed ID: 33207105
    [No Abstract]   [Full Text] [Related]  

  • 3. Azacitidine and Venetoclax in AML.
    Lucijanic M
    N Engl J Med; 2020 Nov; 383(21):2087-2088. PubMed ID: 33207104
    [No Abstract]   [Full Text] [Related]  

  • 4. Azacitidine and Venetoclax in AML.
    Chitikela S; Kumar L; Sahoo RK
    N Engl J Med; 2020 Nov; 383(21):2087. PubMed ID: 33207103
    [No Abstract]   [Full Text] [Related]  

  • 5. [Venetoclax combined with azacitidine in the treatment of elderly patients with acute myeloid leukemia or myeloid sarcoma: Three cases reports and literature review].
    Tian FQ; Zhang LS; Li JH; Tang MQ; Jiang J; Cheng XH; Zhang XC; Jiang M
    Zhonghua Xue Ye Xue Za Zhi; 2020 Aug; 41(8):694-696. PubMed ID: 32942828
    [No Abstract]   [Full Text] [Related]  

  • 6. Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients.
    Zappasodi P; Brociner M; Merati G; Nizzoli ME; Roncoroni E; Boveri E; Castagnola C; Arcaini L
    Ann Hematol; 2021 Apr; 100(4):1111-1113. PubMed ID: 33175198
    [No Abstract]   [Full Text] [Related]  

  • 7. Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.
    Xia L; Tian W; Zhao Y; Jiang L; Qian W; Jiang L; Ge L; Li J; Jin F; Yang M
    Signal Transduct Target Ther; 2023 May; 8(1):176. PubMed ID: 37130896
    [No Abstract]   [Full Text] [Related]  

  • 8. [Efficacy and safety of venetoclax and azacitidine in the treatment of refractory and relapsed acute myeloid leukemia].
    Zong LH; Wu XX; Zhang J; Li MY; Song BQ; Kong JY; Kong X; Hu XH; Bao XB; Qiu HY; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):861-864. PubMed ID: 34788928
    [No Abstract]   [Full Text] [Related]  

  • 9. Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center.
    Secilmis S; Sinan Dal M; Kizil Cakar M; Merdin A; Ahu Baysal N; Altuntas F
    J BUON; 2021; 26(5):2026-2032. PubMed ID: 34761613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A.
    Pratz KW; DiNardo CD; Selleslag D; Li J; Yamamoto K; Konopleva M; Stevens D; Kantarjian H; Traina F; Venditti A; Mayer J; Montez M; Jin H; Duan Y; Brackman D; Zha J; Potluri J; Werner M; Jonas BA
    Am J Hematol; 2022 Nov; 97(11):E416-E419. PubMed ID: 36054316
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax.
    Niswander LM; Chung P; Diorio C; Tasian SK
    Haematologica; 2023 Nov; 108(11):3142-3147. PubMed ID: 37021525
    [No Abstract]   [Full Text] [Related]  

  • 12. Venetoclax plus azacitidine and LDAC induced high response rates in acute myeloid leukaemia in routine clinical practice.
    Liu Y; Zhu L; Lv Z; Mao L; Hu C; Wang J; Zhou Y; Jin J; Meng H; You L
    Br J Haematol; 2023 Jun; 201(5):995-999. PubMed ID: 36999439
    [No Abstract]   [Full Text] [Related]  

  • 13. Azacitidine and venetoclax for post-transplant relapse in a case of CBFA2T3/GLIS2 childhood acute myeloid leukaemia.
    Mishra AK; Mullanfiroze K; Chiesa R; Vora A
    Pediatr Blood Cancer; 2021 Nov; 68(11):e29221. PubMed ID: 34260140
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study.
    Lou Y; Shao L; Mao L; Lu Y; Ma Y; Fan C; Jiang H; Li J; Jin J
    Leuk Res; 2020 Apr; 91():106317. PubMed ID: 32092584
    [No Abstract]   [Full Text] [Related]  

  • 15. Palbociclib promotes the antitumor activity of Venetoclax plus Azacitidine against acute myeloid leukemia.
    Wang A; Fang M; Jiang H; Wang D; Zhang X; Tang B; Zhu X; Hu W; Liu X
    Biomed Pharmacother; 2022 Sep; 153():113527. PubMed ID: 36076608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward an improved understanding of hypomethylating agent and venetoclax therapies.
    DiNardo CD
    Am J Hematol; 2024 Feb; 99(2):152-154. PubMed ID: 38102772
    [No Abstract]   [Full Text] [Related]  

  • 17. Venetoclax in AML: Where We Are and Where We Are Headed.
    Pollyea DA
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S25-S26. PubMed ID: 32862856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia.
    Bouligny IM; Murray G; Ho T; Doyel M; Patel T; Boron J; Tran V; Gor J; Hang Y; Alnimer Y; Zacholski K; Venn C; Wages NA; Grant S; Maher KR
    Leuk Res; 2023 Nov; 134():107370. PubMed ID: 37659346
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study.
    Jonas BA; DiNardo C; Fracchiolla N; Pristupa A; Ishizawa K; Jin J; Konopleva M; Ofran Y; Montesinos P; Kovacsovics T; Jang JH; Kantarjian H; Duan Y; Potluri J; Werner M; Pratz KW
    Am J Hematol; 2022 Nov; 97(11):E422-E425. PubMed ID: 36053878
    [No Abstract]   [Full Text] [Related]  

  • 20. An early glimpse at azacitidine plus venetoclax for myelodysplastic syndromes.
    Pleyer L; Sekeres MA
    Lancet Haematol; 2022 Oct; 9(10):e714-e716. PubMed ID: 36063831
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.